Christina Bredal - Zealand Pharma VP Organization

ZEAL Stock

DKK 738.50 12.00 1.65%

Insider

Christina Bredal is VP Organization of Zealand Pharma AS

Age	38
Phone	45 88 77 36 00
Web	https://www.zealandpharma.com

Zealand Pharma Management Efficiency

The company has return on total asset (ROA) of (0.4816) % which means that it has lost $0.4816 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.4412) %, meaning that it generated substantial loss on money invested by shareholders. Zealand Pharma's management efficiency ratios could be used to measure how well Zealand Pharma manages its routine affairs as well as how well it operates its assets and liabilities.

Compare Zealand Pharma to Peers

Predict price of Zealand Pharma

Zealand Pharma AS has accumulated 647.91 M in total debt with debt to equity ratio (D/E) of 0.1, which may suggest the company is not taking enough advantage from borrowing. Zealand Pharma AS has a current ratio of 4.11, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Zealand Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, Zealand Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Zealand Pharma AS sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Zealand to invest in growth at high rates of return. When we think about Zealand Pharma's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives			INSIDER Age
	Henrik MSc	Bavarian Nordic	58
	Jannick Denholt	FLSmidth Co	N/A
	Pernille Erenbjerg	Genmab AS	52
	Andrew Carlsen	Genmab AS	N/A
	Henrik Ankjr	Ambu AS	N/A
	Annette Terndrup	FLSmidth Co	54
	Rolf Hoffmann	Genmab AS	60
	Laurence Moerlooze	Bavarian Nordic	59
	Mikkel Wagner	Ambu AS	N/A
	Cori Petersen	FLSmidth Co	54
	Paul MSc	Bavarian Nordic	56
	Per Plotnikof	ALK Abell AS	N/A
	Russell Thirsk	Bavarian Nordic	N/A
	Marisol Peron	Genmab AS	N/A
	Christian Houghton	ALK Abell AS	N/A
	Judith MD	Genmab AS	65
	Naja Barrise	FLSmidth Co	N/A
	Nicolai Thomsen	Ambu AS	N/A
	Pr MD	ALK Abell AS	N/A
	Roland Andersen	FLSmidth Co	55
	Rima Nassar	Genmab AS	70

Zealand Pharma AS, a biotechnology company, engages in the discovery, design, and development of peptide-based medicines in Denmark. The company was founded in 1997 and is headquartered in Copenhagen, Denmark. Zealand Pharma operates under Biotechnology classification in Denmark and is traded on Copenhagen Stock Exchange. It employs 360 people. Zealand Pharma AS (ZEAL) is traded on Copenhagen Exchange in Denmark and employs 203 people.

Management Performance

	Return On Equity	-1.44
	Return On Asset	-0.48

Zealand Pharma AS Leadership Team

Elected by the shareholders, the Zealand Pharma's board of directors comprises two types of representatives: Zealand Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Zealand. The board's role is to monitor Zealand Pharma's management team and ensure that shareholders' interests are well served. Zealand Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Zealand Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.

	Henriette Wennicke, Chief Officer
	Lani Morvan, Investor Officer
	Adam MD, Pres CEO
	Hanne Bak, RD Director
	Mads Kronborg, Head Communication
	Ravinder Chahil, Sr Counsel
	Christina Bredal, VP Organization
	Danilo Verge, Head Affairs
	Ivan Moller, Chief Officer
	Jens MD, Head Pharmacology

Zealand Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Zealand Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

	Return On Equity	-1.44
	Return On Asset	-0.48
	Operating Margin	(3.82) %
	Current Valuation	10.33 B
	Shares Outstanding	51.28 M
	Shares Owned By Insiders	0.07 %
	Shares Owned By Institutions	56.21 %
	Price To Earning	12.66 X
	Price To Book	27.77 X
	Price To Sales	36.73 X

Pair Trading with Zealand Pharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Zealand Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Zealand Pharma will appreciate offsetting losses from the drop in the long position's value.

Moving together with Zealand Stock

0.73	NOVO-B	Novo Nordisk AS	Pair Corr
0.71	GMAB	Genmab AS	Pair Corr
0.74	ALK-B	ALK Abell AS	Pair Corr
0.73	BAVA	Bavarian Nordic	Pair Corr

Moving against Zealand Stock

0.51	MAERSK-A	AP Mller	Pair Corr
0.51	MAERSK-B	AP Mller	Pair Corr
0.39	ORPHA	Orphazyme AS	Pair Corr

The ability to find closely correlated positions to Zealand Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Zealand Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Zealand Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Zealand Pharma AS to buy it.

The correlation of Zealand Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Zealand Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Zealand Pharma AS moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Zealand Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Other Information on Investing in Zealand Stock

Zealand Pharma financial ratios help investors to determine whether Zealand Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Zealand with respect to the benefits of owning Zealand Pharma security.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC